
via Fisher Center
New findings suggest a hormone called Lipocalin-2 could be used as a potential treatment for obesity
A hormone that can suppress food intake and increase the feeling of fullness in mice has shown similar results in humans and non-human primates, says a new study published today in eLife.
The hormone, called Lipocalin-2 (LCN2), could be used as a potential treatment in people with obesity whose natural signals for feeling full no longer work.
LCN2 is mainly produced by bone cells and is found naturally in mice and humans. Studies in mice have shown that giving LCN2 to the animals long term reduces their food intake and prevents weight gain, without leading to a slow-down in their metabolism.
“LCN2 acts as a signal for satiety after a meal, leading mice to limit their food intake, and it does this by acting on the hypothalamus within the brain,” explains lead author Peristera-Ioanna Petropoulou, who was a Postdoctoral Research Scientist at Columbia University Irving Medical Center, New York, US, at the time the study was carried out, and is now at the Helmholtz Diabetes Center, Helmholtz Zentrum München, Munich, Germany. “We wanted to see whether LCN2 has similar effects in humans, and whether a dose of it would be able to cross the blood-brain barrier.”
The team first analysed data from four different studies of people in the US and Europe who were either normal weight, overweight or living with obesity. The people in each study were given a meal after an overnight fast, and the amount of LCN2 in their blood before and after the meal was studied. The researchers found that in those who were of normal weight, there was an increase in LCN2 levels after the meal, which coincided with how satisfied they felt after eating.
By contrast, in people who were overweight or had obesity, LCN2 levels decreased after a meal. Based on this post-meal response, the researchers grouped people as non-responders or responders. Non-responders, who showed no increase in LCN2 after a meal, tended to have a larger waist circumference and higher markers of metabolic disease – including BMI, body fat, increased blood pressure and increased blood glucose. Remarkably, however, people who had lost weight after gastric bypass surgery were found to have a restored sensitivity to LCN2 – changing their status from non-responders before their surgery, to responders afterwards.
Taken together, these results mirror those seen in mice, and suggest that this loss of post-meal LCN2 regulation is a new mechanism contributing to obesity and could be a potential target for weight-loss treatments.
After verifying that LCN2 can cross into the brain, the team explored whether treatment with the hormone might reduce food intake and prevent weight gain. To do this, they treated monkeys with LCN2 for a week. They saw a 28% decrease in food intake compared with that before treatment within a week, and the monkeys also ate 21% less than their counterparts who were treated only with saline. Moreover, after only one week of treatment, measurements of body weight, body fat and blood fat levels showed a declining trend in treated animals.
“We have shown that LCN2 crosses to the brain, makes its way to the hypothalamus and suppresses food intake in non-human primates,” concludes senior author Stavroula Kousteni, Professor of Physiology and Cellular Biophysics at Columbia University Irving Medical Center. “Our results show that the hormone can curb appetite with negligible toxicity and lay the groundwork for the next level of LCN2 testing for clinical use.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Treatment for obesity
- Dietary adherence and the fight against obesityon January 25, 2021 at 2:17 pm
While eating less and moving more are the basics of weight control and obesity treatment, finding ways to help people adhere to a weight-loss regimen is more complicated. Understanding what features ...
- Obesity, Impaired Metabolic Health and COVID-19: The Interconnection of Global Pandemicson January 24, 2021 at 8:02 am
In a Nature Reviews Endocrinology article authors from the German Center for Diabetes Research (DZD) highlight the interconnection of obesity and impaired metabolic health with the severity of ...
- Diabetes treatment may protect against COVID-19 mortalityon January 24, 2021 at 3:01 am
A study involving a diverse patient population suggests that a diabetes drug, metformin, may help reduce the risk of COVID-19 mortality.
- For Many, Obesity Is a Literal Headacheon January 22, 2021 at 7:01 am
As worldwide obesity rates continue to soar, new research shows that growing numbers of people are developing a potentially blinding type of weight-linked headache that was once considered rare.
- For Rising Number of People, Obesity Is a Literal Headacheon January 22, 2021 at 5:59 am
(HealthDay News) -- As worldwide obesity rates continue to soar, new research shows that growing numbers of people are developing a potentially blinding type of weight-linked headache that was once ...
Go deeper with Google Headlines on:
Treatment for obesity
Go deeper with Bing News on:
Lipocalin-2
- Scientists discover link between nicotine and breast cancer metastasison January 21, 2021 at 10:03 am
Breast cancer is the second most common cancer among women in the United States, and cigarette smoking is associated with a higher incidence of breast cancer spread, or metastasis, lowering the ...
- Nicotine promotes breast cancer lung metastasis, finds studyon January 21, 2021 at 8:30 am
Breast cancer is the second most common cancer among women in the United States, and cigarette smoking is associated with a higher incidence of breast cancer spread, or metastasis, lowering the ...
- Role of Biomarkers in the Diagnosis and Prognosis of Acute Kidney Injury in Patients With Cardiorenal Syndromeon January 17, 2021 at 4:00 pm
Figure 2 illustrates the delay in rise of serum creatinine compared with biomarkers such as B-type natriuretic peptide (BNP) and neutrophil gelatinase-associated lipocalin (NGAL), which rise ...
- This hormone may help beat obesityon January 16, 2021 at 3:05 am
In a recent study at Columbia University Irving Medical Center, researchers found that a hormone that can suppress food intake and increase the feeling of fullness has shown similar results in humans ...
- BioPorto Diagnostics says it has gained the CE mark in Europe for its NGALds kidney teston December 30, 2020 at 9:03 am
The NGALds test is designed to deliver a semi-quantitative NGAL (neutrophil gelatinase-associated lipocalin) result in under 15 minutes ... including tests for SARS-CoV-2 (COVID-19) and sepsis, it ...